Literature DB >> 12204530

The RB and p53 pathways in cancer.

Charles J Sherr1, Frank McCormick.   

Abstract

The life history of cancer cells encompasses a series of genetic missteps in which normal cells are progressively transformed into tumor cells that invade surrounding tissues and become malignant. Most prominent among the regulators disrupted in cancer cells are two tumor suppressors, the retinoblastoma protein (RB) and the p53 transcription factor. Here, we discuss interconnecting signaling pathways controlled by RB and p53, attempting to explain their potentially universal involvement in the etiology of cancer. Pinpointing the various ways by which the functions of RB and p53 are subverted in individual tumors should provide a rational basis for developing more refined tumor-specific therapies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12204530     DOI: 10.1016/s1535-6108(02)00102-2

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  542 in total

Review 1.  Mouse models of p53 functions.

Authors:  Guillermina Lozano
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

2.  The p44/wdr77-dependent cellular proliferation process during lung development is reactivated in lung cancer.

Authors:  Z Gu; F Zhang; Z-Q Wang; W Ma; R E Davis; Z Wang
Journal:  Oncogene       Date:  2012-06-04       Impact factor: 9.867

3.  Suppression of the novel ER protein Maxer by mutant ataxin-1 in Bergman glia contributes to non-cell-autonomous toxicity.

Authors:  Hiroki Shiwaku; Natsue Yoshimura; Takuya Tamura; Masaki Sone; Soichi Ogishima; Kei Watase; Kazuhiko Tagawa; Hitoshi Okazawa
Journal:  EMBO J       Date:  2010-06-08       Impact factor: 11.598

4.  Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.

Authors:  W Ruprecht Wiedemeyer; Ian F Dunn; Steven N Quayle; Jianhua Zhang; Milan G Chheda; Gavin P Dunn; Li Zhuang; Joseph Rosenbluh; Shujuan Chen; Yonghong Xiao; Geoffrey I Shapiro; William C Hahn; Lynda Chin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

Review 5.  [Malignancy potential of precursor lesions: determination using molecular markers].

Authors:  A Jung
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

Review 6.  New careers for antioxidants.

Authors:  Douglas E Brash; P A Havre
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

7.  RB reversibly inhibits DNA replication via two temporally distinct mechanisms.

Authors:  Steven P Angus; Christopher N Mayhew; David A Solomon; Wesley A Braden; Michael P Markey; Yukiko Okuno; M Cristina Cardoso; David M Gilbert; Erik S Knudsen
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

8.  Induction of a G1-S checkpoint in fission yeast.

Authors:  Cathrine A Bøe; Marit Krohn; Gro Elise Rødland; Christoph Capiaghi; Olivier Maillard; Fritz Thoma; Erik Boye; Beáta Grallert
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

9.  Cyclin D1 overexpression perturbs DNA replication and induces replication-associated DNA double-strand breaks in acquired radioresistant cells.

Authors:  Tsutomu Shimura; Yasushi Ochiai; Naoto Noma; Toshiyuki Oikawa; Yui Sano; Manabu Fukumoto
Journal:  Cell Cycle       Date:  2013-02-06       Impact factor: 4.534

10.  Synthetic lethality of retinoblastoma mutant cells in the Drosophila eye by mutation of a novel peptidyl prolyl isomerase gene.

Authors:  Kyle A Edgar; Marcia Belvin; Annette L Parks; Kellie Whittaker; Matt B Mahoney; Monique Nicoll; Christopher C Park; Christopher G Winter; Feng Chen; Kim Lickteig; Ferhad Ahmad; Hanife Esengil; Matthew V Lorenzi; Amanda Norton; Brent A Rupnow; Laleh Shayesteh; Mariano Tabios; Lynn M Young; Pamela M Carroll; Casey Kopczynski; Gregory D Plowman; Lori S Friedman; Helen L Francis-Lang
Journal:  Genetics       Date:  2005-03-02       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.